热门资讯> 正文

Genmat结束晚期肿瘤学资产acasunlimab的开发

2025-12-29 23:07

Genmab A/S(GMAB) 0
Merus(MRUS) 0

Genmab (GMAB) has decided to discontinue development of acasunlimab, which was in phase 3 for non-small cell lung cancer, to focus on other assets in its pipeline as well as its marketed product, Epkinly (epcoritamab), which is approved for lymphomas.
The asset , a bispecific antibody targeting PD-L1 and 4-1BB, was also in phase 2 for advanced melanoma and phase 1 for solid tumors.
The Danish pharma said the decision would not impact its 2025 financial guidance.
Separately, Genmab noted that it has completed its tender offer of outstanding shares of Dutch pharma Merus (MRUS) as part of the latter's $8B acquisition.

More on Genmab

Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions - Slideshow
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma
Genmab Q3 2025 Earnings Preview

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。